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Introduction: Unfractionated heparin (UFH), low molecular weight heparin or fondaparinux are recommended
for venous thromboembolism (VTE) prophylaxis in acutely ill medical patients. There are limited data on the
safety of fondaparinux for VTE prophylaxis in ischemic stroke. We examined adverse event frequency in
hospitalized patients with ischemic stroke who received VTE prophylaxis with fondaparinux versus UFH.
Materials and Methods: We performed a propensity score matched analysis on a retrospective cohort of 644
consecutive patients with acute ischemic stroke receiving fondaparinux (n = 322) or UFH (n = 322) for VTE
prophylaxis. Patients who received intravenous tPA and continuous intravenous infusions of UFHwere excluded.
The primary outcomewasmajor hemorrhage (intracranial or extracranial) and the secondary outcomewas total
hemorrhage (major and minor hemorrhage) during hospitalization. We also examined the rate of symptomatic
VTE.
Results:Mean age of the matched cohort was 71.3 ± 14.1 years, median NIHSS score was 4 (IQR 1–11), median
duration of anticoagulant exposure was 5 (IQR 3–8) days, and 98.1% received antiplatelet medications. In the
matched cohort, therewere less observedmajor hemorrhages in the fondaparinux group 1.2% (4/322) compared
to UFH 3.7% (12/322), but this differencewas not signiﬁcant (OR=0.33, 95% CI 0.08–1.10, p= 0.08). Therewere
also no signiﬁcant differences in total hemorrhage (p = 0.15), intracranial hemorrhage (p = 0.48), major
extracranial hemorrhage (p = 0.18) and symptomatic VTE (p = 1.00) between the groups.
Conclusions: Fondaparinux is not associated with increased hemorrhagic complications compared with UFH in
patients with ischemic stroke. There were low rates of symptomatic VTE in both groups.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Recent worldwide estimates of incident stroke are 16.9 million
cases, 5.9 million stroke deaths, 33 million stroke survivors, and 102
million disability-adjusted life-years (DALYs) lost reﬂecting an overall
increasing global burden of stroke (1990-2010) [1]. Ischemic stroke ac-
counts for 87%of all strokes, leading to high rates of disability and death;
50% of survivors have hemiparesis and 30% require assistance to walk
[2]. Prospective studies of hospitalized patients with acute ischemicey and C. T. Hackett
, Comprehensive Stroke Center,
ite 500, Pittsburgh, PA 15212.
script.
. This is an open access article understroke have demonstrated a high prevalence of total VTE (20–40%) in
the absence of VTE prophylaxis [3,4], however, the incidence of symp-
tomatic VTE is signiﬁcantly lower (b1%) [5]. Expert consensus group
guidelines recommend low dose unfractionated heparin (LDUH), low
molecular weight heparin (LMWH) or intermittent pneumatic com-
pression (IPC) for VTE prophylaxis in patients with acute ischemic
stroke and restricted mobility [6]. Unfractionated heparins and LMWH
reduce the incidence of prospectively identiﬁed asymptomatic deep
venous thrombosis (DVT) and symptomatic pulmonary embolism
(PE), but are associated with increased major extracranial hemorrhage
and nonsigniﬁcant trends toward increased symptomatic intracranial
hemorrhage [7–9]. Fondaparinux was associated with decreased
asymptomatic and symptomatic VTE without increased major hemor-
rhage in a prospective randomized placebo controlled trial of VTE
prophylaxis in non-ambulatory patients age N 60 years with acute
medical conditions [10]. This study excluded patients with ischemic
stroke considered to be at increased risk of hemorrhage [10]. There isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ed to fondaparinux for VTE prophylaxis in patientswith ischemic stroke.
Fondaparinux sodium (Arixtra; Aspen) mediates its antithrombotic
effect through highly selective factor Xa inhibition and has several
favorable antithrombotic properties for VTE prophylaxis in stroke
patients: 1) 100% bioavailability; 2) rapid onset of action (1.7 hours);
3) 24-hour antithrombotic activity (half-life 14–18 hours); 4) no
effect on measures of prothrombin time, APTT or platelet function;
and 5) linear pharmacokinetics (low interindividual variability) [11].
Additionally, fondaparinux does not bind platelet factor 4 complex,
which suggests a lower theoretical risk of heparin-induced thrombocy-
topenia (HIT) compared with LDUH or LMWH [12,13].
We sought to provide data about the safety of fondaparinux by
examining adverse hemorrhagic events among ischemic stroke patients
treatedwith fondaparinux or UFH for VTE prophylaxis. The null hypoth-
esis was that therewould be no signiﬁcant difference in adverse hemor-
rhagic event rates between the fondaparinux and UFH groups during
acute hospitalization for ischemic stroke.
Materials and Methods
Standard Protocol Approvals, Registrations, and Patient Consents
This retrospective cohort study was approved by an ethical stan-
dards committee; the Institutional Review Board of Allegheny General
Hospital, in order to examine health records of patients at our institu-
tion. Fondaparinux was approved by the anticoagulation management
subcommittee of AlleghenyGeneral Hospital for off-label use in patients
with ischemic stroke for VTE prophylaxis.
Study Design and Population
FromMarch 2009 toNovember 2012, a total of 1275 consecutive pa-
tients was admitted with ischemic stroke and received VTE prophylaxis
with fondaparinux 2.5 mg subcutaneously once daily or UFH 5000 units
subcutaneously every 8 hours. VTE anticoagulant was not randomly
assigned and there were no predetermined criteria for use of
fondaparinux or UFH for VTE prophylaxis in patients with ischemic
stroke. There were no other signiﬁcant systematic changes to patient
management instituted during this time period.
Inclusion criteria were: 1) age N 18 years; 2) ﬁnal diagnosis of
ischemic stroke; and 3) fondaparinux or UFH exposure ≥ 48 hours.
We surmised that brief exposures to VTE anticoagulant would be
insufﬁcient to assess the risk of hemorrhagic complications.
Exclusion criteria were: 1) a ﬁnal diagnosis other than ischemic
stroke; 2) creatinine clearance (CrCl) b 30milliliters perminute because
fondaparinuxwould be contraindicated; 3) intravenous tissue plasmin-
ogen activator or intravenous heparin administration during hospitali-
zation; and 4) no measured weight in the medical record. The criteria
for a ﬁnal diagnosis of ischemic stroke were based upon accepted
standard clinical and radiographic deﬁnitions [14]. Patients receiving
both warfarin and concomitant VTE prophylaxis (fondaparinux or
UFH) during periods of subtherapeutic anticoagulation (INR b 2.0)
were included in the study.
Data Collection and Management
Consecutive patients who received fondaparinux or UFH during the
study period were identiﬁed by a health records analyst (M.P.) at Alle-
gheny General Hospital using Sunrise Acute Care software (Allscripts
Healthcare Solutions Inc., Chicago, IL). The health records analyst was
unaware of the study design and was not directly involved in the
study. Once patients were identiﬁed, data were collected by means of
a review of paper and electronic health records, discharge summaries,
diagnostic imaging studies and laboratory reports. Datawere abstracted
onto standardized case report forms by four investigators (S.R., C.H.,M.T., and K.M.). Patient demographics, stroke risk factors, admission
National Institute of Health Stroke Scale (NIHSS) score, CrCl, weight,
duration of fondaparinux and UFH exposure, use of IPC applied to the
calf (Covidien, MA, USA), concomitant use of antithrombotic and
antiplatelet agents, hemorrhagic complications, and VTE events were
collected and reviewed. Hemorrhagic risk factors (age, admission
NIHSS, diabetes, atrial ﬁbrillation, weight and CrCl) were collected at
baseline. Exposure to antiplatelet medications and warfarin were
collected during the course of hospitalization up to an outcome event
or discharge from the hospital. Similarly, the duration of fondaparinux
or UFH was deﬁned as the number of days of exposure during hospital-
ization up to an outcome event or discharge from the hospital without
an outcome event.
Outcome Measures
Theprimary outcomewasmajor hemorrhage during hospitalization,
which included both symptomatic intracranial hemorrhage and major
extracranial hemorrhage. We used the International Society on Throm-
bosis and Haemostasis (ISTH) deﬁnition of major hemorrhage, deﬁned
as symptomatic bleeding in a critical area or organ, or a bleed that
resulted in a decrease in baseline hemoglobin ≥ 20 g/L or transfusion
requiring ≥ 2 units of blood, or when a hemorrhagic event was fatal
[15]. Intracranial hemorrhage was diagnosed by CT head or MRI brain
interpreted by neuroradiologists. All radiographic images of intracranial
hemorrhages were also reviewed by a vascular neurologist (A.T.)
blinded to anticoagulant exposure. An adverse hemorrhagic event was
deﬁned by the presence of a new symptomatic parenchymal hematoma
or extra-axial hemorrhage. Asymptomatic hemorrhagic infarction
characterized by petechial hemorrhage only within the area of ischemic
infarction (hemorrhagic infarction types 1 or 2) without clinical deteri-
oration, was not designated as an adverse hemorrhagic event [16].
The secondary outcome was total hemorrhage (major and minor).
Minor extracranial hemorrhage included epistaxis lasting more than
5minutes or requiring intervention, gastrointestinal bleeds notmeeting
the deﬁnition for major hemorrhage, ecchymosis or hematoma larger
than 5 cm at its widest point and hematuria not associated with urinary
catheter trauma [17].
We also examined new venous thrombotic events during hospitali-
zation, speciﬁcally, symptomatic deep venous thrombosis (DVT) and
fatal/nonfatal pulmonary embolism (PE). All adverse events occurred
while patients were receiving treatment with UFH or fondaparinux.
Diagnostic studies to detect DVT or PE were performed when
clinically suspected by the treating physician. Patients did not undergo
diagnostic screening studies for DVT. All DVT and PE events were there-
fore designated symptomatic in this study. DVT eventswere categorized
into proximal and distal sites of venous thrombosis and thrombotic
events related to indwelling venous catheters were not considered as
DVT events. DVT was diagnosed using standardized protocols for com-
pression duplex ultrasound (CDU) of the upper or lower extremity
and all studies were completed in a dedicated vascular laboratory
accredited by the Intersocietal Commission for Accreditation of Vascular
Laboratories (ICAVL). All cases of PE were diagnosed by pulmonary CT
angiography interpreted by chest radiologists.
Statistical Analysis
Descriptive and frequency statistical analyses were performed and
comparisons were made with SPSS (version 20.0, SPSS Inc.). Summary
statistics were computed for demographics, antithrombotic and antico-
agulant agents, and primary and secondary outcomes. Univariate analy-
ses (Student t-test, Mann Whitney, Chi square or Fisher’s exact where
appropriate) of variables associated with major hemorrhagic complica-
tions were performed. A p value b 0.05 was considered signiﬁcant.
Because fondaparinux or UFH was not randomly assigned in the
study population and there were a low number of outcome events
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matched analysis to reduce the risk of bias owing to confounding
[18–20]. Propensity score matching is a method of statistical analysis
that reduces systematic imbalance of chosen covariates between treat-
ment groups in an observational study, allowing for a more precise
estimation of the effect of a treatment on the outcome of interest. The
fondaparinux and UFH groups were matched by pair matching (1:1),
without replacement, using a caliper width of 0.2 of the standard devi-
ation of the logits of the propensity scores [19,21]. The propensity score
was estimated using a logistic regression model in which receipt of VTE
anticoagulant (fondaparinux versus UFH) was regressed on eleven
baseline covariates derived from factors reported or thought to be asso-
ciated with the primary outcome of interest (major hemorrhage): age,
gender, admission NIHSS (stroke severity), weight, CrCl, diabetes,Fig. 1. Study Proﬁle. CrCl indicates creatinine clearance; NIHSS, Nationalantiplatelet medication, atrial ﬁbrillation, warfarin, duration of VTE
anticoagulant exposure and IPC use [22]. The method of standardized
differences was used to assess balance of the covariates before and
after matching with an absolute standardized difference b10% consid-
ered desirable [20]. In the ﬁnal propensity score matched sample, we
compared the main outcome (major hemorrhages), total hemorrhages,
intracranial hemorrhage, major extracranial hemorrhage and symp-
tomatic VTE events between those receiving fondaparinux and UFH
using McNemar’s test for the binary variables.
Results
Of the 1275 patients reviewed, a total of 866 (70%) patients was
included in the unmatched analysis. The unmatched cohort includedInstitute of Health Stroke Scale; tPA, tissue plasminogen activator.
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group. The propensity score matched cohort was comprised of 322
patients in the fondaparinux group and 322 patients in the UFH group.
Fig. 1 presents the details of the 409 patients who were excluded from
the study.
Baseline clinical variables before and after propensity scorematched
analysis are presented in Table 1. After propensity score matching, the
absolute standardized differences in all eleven baseline covariates
were b10% suggesting appropriate balance between the fondaparinux
and UFH groups. A visual representation of the reduction of imbalance
of covariates after propensity matching is presented in Fig. 2. Nearly
all patients received antiplatelet medication during hospitalization
(Table 1). In the matched cohort, there were no signiﬁcant differences
in the exposure to aspirin (fondaparinux group 96.3% vs UFH group
95%, p = 0.56) or clopidogrel (fondaparinux group 18.3% vs. UFH
group 19.6%, p = 0.76). No patients received target speciﬁc oral
anticoagulants.
Primary and secondary adverse outcomes in the unmatched and
propensity score matched cohorts are presented in Table 2. In the
matched analysis, we found a nonsigniﬁcant trend toward less major
hemorrhages in the fondaparinux group, 1.2% (4/322) compared to
the UFH group, 3.7% (12/322), (OR 0.33, 95% CI 0.08–1.10, p = 0.08).
Similarly, there was a nonsigniﬁcant trend toward less total hemor-
rhages in the fondaparinux group, 1.6% (5/322) compared with the
UFH group, 3.7% (12/322), (OR 0.42, 95% CI 0.12–1.27, p = 0.15).
Symptomatic VTE were detected in 0.6% (2/322) of patients receiving
fondaparinux and 0.9% (3/322) of patients administered with UFH
(OR 0.67, 95%CI 0.06–5.82, p = 1.00).
Discussion
The main ﬁnding of this study was that patients hospitalized for
ischemic stroke receiving VTE prophylaxis with fondaparinux had a
similar, low rate of major hemorrhage 1.2% (4/322) compared with
UFH 3.7% (12/322), p= 0.08, based upon the propensity score matched
analysis. The fondaparinux group also had a similar incidence of
total hemorrhage 1.6% (5/322) compared with the UFH group 3.7%
(12/322), p = 0.15. Major hemorrhages were comprised mainly of
extracranial hemorrhages and there were no intracranial hemorrhages
in the fondaparinux group.
A previous study found that the rate of major hemorrhage in
patients receiving fondaparinux in patients with “acute medicalTable 1






Risk factors for stroke or VTE
Age (years) 68.72 ± 13.98 71.45 ± 14.73
Sex (female) 234 (47.6) 196 (52.4)
NIHSS 4 (IQR 2–10) 3 (IQR 0–11)
Weight (kg) 83.50 ± 20.22 81.01 ± 21.44
Creatinine clearance (mL/min) 93.82 ± 46.55 75.02 ± 38.36
Atrial ﬁbrillation 123 (25.0) 118 (31.6)
Diabetes 165 (33.5) 146 (39.0)
Hypertension 388 (78.9) 312 (83.4)
VTE anticoagulant administration (days) 4 (IQR 3–6) 5 (IQR 3–6)
Previous stroke/TIA 94 (19.1) 77 (20.6)
Previous VTE 10 (2.0) 9 (2.4)
Intermittent pneumatic compression 264 (53.7) 235 (62.8)
Concomitant medications
Antiplatelet medications 487 (99.0) 357 (95.5)
Warfarin 61 (12.4) 36 (9.6)
All values are mean ± standard deviation or n (%)
NIHSS, National Institute of Health stroke scale; TIA, transient ischemic attack; VTE, venous thr
a Standardized difference.conditions” excluding ischemic stroke was 0.2% (1/425) [10]. In
contrast, enoxaparin for VTE prophylaxis has been studied in patients
with ischemic stroke with a reported rate of major hemorrhage of
1.3% (11/877), comprised of intracranial hemorrhages 0.5% (4/877)
and extracranial hemorrhages 0.8% (7/877) [17]. We applied the same
strict deﬁnitions of safety outcomes reported in prospective VTE pro-
phylaxis trials of fondaparinux and enoxaparin and found comparable
low rates of total and major hemorrhages in patients with ischemic
stroke treated with fondaparinux [10,17]. A retrospective study of
fondaparinux, UFH and LMWH for VTE prophylaxis in patients with
ischemic stroke reported major hemorrhages in the UFH group of 6.2%
(22/353) versus the fondaparinux group of 0.7% (2/285) [22]. This
study included patients receiving intravenous thrombolytic therapy,
which may have increased the risk of major hemorrhages in the UFH
group. We excluded patients receiving intravenous thrombolytic from
our study. A pooled analysis of eight large randomized controlled trials
(n=13,085) of fondaparinux versus placebo (LMWHor LDUH) inmed-
ical and surgical patients reported that age, fondaparinux, lower body
weight and lower CrCl were predictors of major hemorrhage [23]. We
reduced bias in our study by matching patients based on age, body
weight and CrCl, in addition to a number of other covariates (gender,
NIHSS, atrial ﬁbrillation, diabetes, antiplatelet use, warfarin use, the
duration of VTE anticoagulant and IPC use) in order to examine the
relationship between VTE anticoagulant (fondaparinux versus UFH)
and hemorrhagic events. Though our study differs in design and
methodology from prospective trials, we found no evidence that
fondaparinux increased the risk of hemorrhagic complications relative
to UFH in patientswith ischemic stroke ofwide ranging severity [10,17].
The observed symptomatic VTE rates were no different in the two
groups; 0.6% (2/322) in the fondaparinux group, and 0.9% (3/322) in
the UFH group, (OR 0.67, 95% CI 0.06–5.82, p = 1.00), in the matched
analysis. Patients did not undergo screening CDU and cases of symp-
tomatic DVT or PE were identiﬁed when treating physicians suspected
VTE and requested diagnostic studies reﬂecting “real life” practice.
Medical records were examined for VTE events during hospitalization
and did not extend into the post-hospitalization phase. We cannot,
therefore, provide data regarding the rate of asymptomatic DVT during
hospitalization or the rate of VTE detected after hospitalization as
demonstrated in prospective trials of extended prophylaxis [10,17].
IPC was applied in 59.9% (193/322) of the fondaparinux group and
59.9% (193/322) of the UFH group, which may have also reduced the
risk of symptomatic VTE independent of the VTE anticoagulants [24].ity score matched analysis.






-19.5 71.77 ± 13.14 70.77 ± 14.97 7.1
-9.6 171 (53.1) 167 (51.9) 2.4
-3.0 4 (IQR 2–11) 3 (IQR 0–12) 5.1
11.9 80.11 ± 18.38 80.93 ± 21.57 -4.1
44.1 77.02 ± 30.58 78.64 ± 39.53 -4.6
-14.7 98 (30.4) 93 (28.9) 3.3
-11.5 113 (35.1) 120 (37.3) -4.6
-11.5 267 (82.9) 263 (81.7) 3.1
-27.5 5 (IQR 3–7) 5 (IQR 3–7) 2.0
-3.8 59 (18.3) 67 (20.8) -6.3
-2.7 5 (1.6) 9 (2.8) -8.2
-18.5 193 (59.9) 193 (59.9) 0.0
21.5 317 (98.4) 315 (97.8) 4.4
9.0 38 (11.8) 32 (9.9) 6.1
omboembolism.
Fig. 2. Standardized difference bias across covariates. CrCl indicates creatinine clearance; NIHSS, National Institute of Health Stroke Scale.
253C.T. Hackett et al. / Thrombosis Research 135 (2015) 249–254There are several limitations to our study. VTE anticoagulantwas not
randomly assigned and data were obtained retrospectively, which may
have introduced bias. Patient groups were generally well balanced in
terms of baseline characteristics and signiﬁcant differences in baseline
covariates were reduced through propensity score matching. There is
the potential for residual confounding from unknown factors. Data
collected for baseline characteristics and outcomes were reliably
available within the medical records and there were no missing data.
In addition, we limited our investigation to acute hospitalization and
we did not examine hemorrhagic complications and symptomatic VTETable 2









Hemorrhagic complications (total)c 6 (1.2) 14 (3.7) 0.32 (0.
Major hemorrhagic complicationsd 4 (0.8) 14 (3.7) 0.21 (0.
Intracranial hemorrhage 0 (0.0) 2 (0.5) -
Major extracranial hemorrhagee 4 (0.8) 12 (3.2) 0.25 (0.
Minor extracranial hemorrhagef 2 (0.4) 0 (0.0) -
VTE Complications
Symptomatic venous thrombotic events (total) 2 (0.4) 5 (1.3) 0.30 (0.
Pulmonary embolism 2 (0.4) 1 (0.3) 1.52 (0.
Symptomatic DVT (total)g 0 (0.0) 4 (1.1) -
Proximal DVT 0 (0.0) 1 (0.3) -
Distal DVT 0 (0.0) 2 (0.5) -
Proximal and distal DVT 0 (0.0) 1 (0.3) -
All values are n (%). OR indicates odds ratio; DVT, deep venous thrombosis; VTE, venous throm
a All p values are two-sided Fisher’s exact or chi square, as appropriate, for the unmatched a
b All p values are McNemar’s for the matched analysis.
c Hemorrhagic complications (total) included all intracranial hemorrhages, major extracran
d Major hemorrhagic complications were deﬁned as all intracranial hemorrhages and major
e Major extracranial hemorrhagic complications were deﬁned as a hemorrhage that resulted
bleed in a critical area or organ [15].
f Minor extracranial hemorrhage included epistaxis lastingmore than 5minutes or needing i
or hematoma larger than 5 cm at its widest point and hematuria not associated with urinary c
g All DVTs were unrelated to indwelling venous catheter placement and considered symptoevents post-hospitalization. Patient outcomes were adjudicated in an
unblinded fashion, which may have resulted in ascertainment bias.
We minimized the risk of this bias by using strict a priori deﬁnitions of
outcome events. We are limited in our conclusions regarding the efﬁca-
cy of fondaparinux for VTE prophylaxis in ischemic stroke as compared
to UFH because we were not able to examine asymptomatic VTE. We
found a low rate of observed symptomatic VTE during hospitalization
in a large cohort and recognize that a rigorous evaluation of the efﬁcacy
of fondaparinux in ischemic strokewould require a prospective study of
extended VTE prophylaxis [10,17]. Finally, based upon our sample size,unmatched and propensity score matched cohorts.
Propensity Score Matched Cohort





OR (95% CI) p valueb
12–0.83) 0.01 5 (1.6) 12 (3.7) 0.42 (0.12–1.27) 0.15
07–0.65) 0.003 4 (1.2) 12 (3.7) 0.33 (0.08–1.10) 0.08
0.19 0 (0.0) 2 (0.6) - 0.48
08–0.77) 0.01 4 (1.2) 10 (3.1) 0.40 (0.09–1.39) 0.18
0.51 2 (0.6) 0 (0.0) - 0.48
06–1.56) 0.25 2 (0.6) 3 (0.9) 0.67 (0.06–5.82) 1.00
14–16.85) 1.00 2 (0.6) 1 (0.3) 2.00 (0.10–117.99) 1.00
0.03 0 (0.0) 3 (0.9) - 0.25
0.43 0 (0.0) 1 (0.3) - 1.00
0.19 0 (0.0) 1 (0.3) - 1.00
0.43 0 (0.0) 1 (0.3) - 1.00
boembolism.
nalysis.
ial hemorrhages and minor extracranial hemorrhages.
extracranial hemorrhages.
in: death, drop of hemoglobin≥ 20 g/L, transfusion of≥ 2 units of blood or a symptomatic
ntervention, gastrointestinal bleeds notmeeting the deﬁnition formajor bleed, ecchymosis
atheter trauma [17].
matic.
254 C.T. Hackett et al. / Thrombosis Research 135 (2015) 249–254the study may be underpowered for a deﬁnitive analysis of safety. The
non-signiﬁcant lower rates of major hemorrhagic complications in the
fondaparinux group compared with the UFH group may represent a
type II error. Despite these limitations, our study reveals similar low
rates of hemorrhagic complications and symptomatic VTE in matched
groups of patients with ischemic stroke treated with fondaparinux-
and UFH for VTE prophylaxis.
Conclusions
Fondaparinux for VTE prophylaxis in patientswith ischemic stroke is
not associatedwith an increased risk ofmajor hemorrhage or total hem-
orrhage in comparison to standard prophylaxis with UFH. There were
low rates of hemorrhage and symptomatic VTE in both fondaparinux-
and UFH-treated patients. Our ﬁndings provide supportive safety data
for a prospective trial of extended VTE prophylaxis with fondaparinux
in acute ischemic stroke.
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